🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseHas anyone dealt with alt normalization rates on glp-1? Page 4

Has anyone dealt with alt normalization rates on glp-1?

laura_annarbor Tue, Oct 14, 2025 at 9:24 PM 23 replies 1,414 viewsPage 4 of 5
AttorneyGrant
Member
567
2,890
Apr 2024
Washington, DC
Oct 15, 2025 at 3:04 AM#16

Just wanted to say — for anyone reading this Has anyone dealt thread who is feeling discouraged: it gets better. The first few weeks are the hardest. Hang in there. 💪

47 1Dr.SleepRoch, laura_annarbor, JenMemphis and 44 others
Reply Quote Save Share Report
bbq_ray_KC
Member
378
1,678
Jul 2024
Kansas City, KS
Oct 15, 2025 at 3:21 AM#17

laura_annarbor's experience with Has anyone dealt with alt resonates deeply with mine. I went through almost the identical process — starting dose, titration timeline, side effects, everything.

The main difference: I titrated faster. But the overall trajectory has been remarkably similar. Down 32 lbs in 7 months.

One thing I would add that laura_annarbor did not mention: the relationship with food fundamentally changed.

10 4MikeFit_NJ, InsuranceTom, WendyG_ATL and 7 others
Reply Quote Save Share Report
Dr.EndoIndy
Member
267
1,234
Oct 2024
Indianapolis, IN
Oct 15, 2025 at 3:38 AM#18

Saving this for reference. Quality thread.

25 3marcus_mpls, DeniseRN_TPA, SandraNC_45 and 22 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
PedsEndoPhilly
Member
345
1,890
Jun 2024
Philadelphia, PA
Oct 15, 2025 at 3:55 AM#19

As a healthcare provider, I want to add some clinical context to this discussion on Has anyone dealt with alt normalization.

Building on what laura_annarbor said — the evidence base here is well-established. The key publications to reference are from the FLOW program[1].

Key clinical points:

  1. Efficacy is dose-dependent and typically requires 4-5 weeks to reach steady state
  2. Side effect profile is predictable and usually manageable with standard protocols
  3. Monitoring should include baseline labs and follow-up at 3-month intervals
  4. Patient education significantly improves outcomes and adherence

Standard disclaimer: this is educational, not individualized medical advice.

References:
[1] See thread title for relevant study identification.
Last edited: Oct 15, 2025 at 8:55 AM
11 2Dr.LeslieOBGYN, MikeNYC_runner and 8 others
Reply Quote Save Share Report
SkepticalSean
Member
98
345
Jan 2025
Maine
Oct 15, 2025 at 4:12 AM#20

Subscribing to this thread. Has anyone dealt with alt is exactly what I've been researching. 🙏

43 22Dr.LipidDallas, alex_tucson, kevin_tulsa and 40 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register